Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  ANGLE plc    AGL   GB0034330679

ANGLE PLC (AGL)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/22 11:35:25 am
54.5 GBp   +2.83%
2018FTSE 100 Up Ahead of Chancellor Hammond's Speech
DJ
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/16/2019 01/17/2019 01/18/2019 01/21/2019 01/22/2019 Date
53.5(c) 53.5(c) 53(c) 53(c) 54.5 Last
287 868 84 925 145 264 60 098 233 513 Volume
+1.90% 0.00% -0.93% 0.00% +2.83% Change
More quotes
Financials (GBP)
Sales 2019 1,30 M
EBIT 2019 -10,1 M
Net income 2019 -9,10 M
Finance 2019 9,10 M
Yield 2019 -
Sales 2020 2,70 M
EBIT 2020 -9,80 M
Net income 2020 -9,20 M
Finance 2020 0,30 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 51,5x
EV / Sales2020 28,1x
Capitalization 76,0 M
More Financials
Company
ANGLE plc is a holding company. The Company's principal activity is undertaken in relation to the commercialization of its Parsortix cell separation system, with deployment in non-invasive cancer diagnostics. The Company is a specialist medical diagnostic company, which offers products for cancer... 
More about the company
Latest news on ANGLE PLC
01/10ANGLE : Breakthrough cancer research using parsortix
PU
2018ANGLE : Issue of LTIP Options and Share Options
PU
2018ANGLE : Leading us hematopathologist appointed as advisor
PU
2018ANGLE : Acquisition of outstanding shares
PU
2018ANGLE : Appointment of Dr Jan Groen as NED
PU
2018FTSE 100 Up Ahead of Chancellor Hammond's Speech
DJ
2018ANGLE : Parsortix shows capability to harvest fetal cells
PU
2018ANGLE : Good Progress with FDA Studies
PU
2018ANGLE : Parsortix shows evidence of CTCs in glioblastoma
PU
2018ANGLE : Preliminary Results for year ended 30 April 2018
PU
More news
Analyst Recommendations on ANGLE PLC
More recommendations
Sector news : Bio Therapeutic Drugs
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Bio Therapeutic Drugs
Chart ANGLE PLC
Duration : Period :
ANGLE plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANGLE PLC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Andrew D. W. Newland Chief Executive Officer & Executive Director
Garth Robert Selvey Non-Executive Chairman
Martin Cooke Director-Operations & Regulatory Affairs
Ian Francis Griffiths CFO, Secretary & Executive director
Jay Lewington Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
ANGLE PLC35.90%98
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS17.49%49 757
REGENERON PHARMACEUTICALS12.14%44 532
GENMAB-3.09%9 527
NEUROCRINE BIOSCIENCES, INC.28.18%8 300